Treatment advances - When and how to inform the public?

British Journal of Rheumatology

Volumn 35, Issue 11, 1996, Pages 1175-1177

  Deighton, C ^a   Doherty, M ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; STEROID; TUMOR NECROSIS FACTOR;

ALTERNATIVE MEDICINE; GENERAL PRACTITIONER; HUMAN; MEDICAL INFORMATION; PATIENT EDUCATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; UNITED KINGDOM;

ARTHRITIS, RHEUMATOID; GREAT BRITAIN; HEALTH EDUCATION; HUMANS; OSTEOPOROSIS; RHEUMATOLOGY;

EID: 1542680958     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. Elliott MJ, Maini R, Feldman M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
2. Kirwan J. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
3. MacFarlane A, Gaffin J, Jones R, Seifert M. General public education. Ann Rheum Dis 1991;50:435-8.
4. Morrison E, Capell H. Corticosteroids in the management of rheumatoid arthritis. Br J Rheumatol 1996;35:2-4.